Paolo Paoletti - Articles and news items

GlaxoSmithKline logo

GSK receives marketing authorisation from the European Commission for Tafinlar™ (dabrafenib)

Industry news, News / 2 September 2013 / GlaxoSmithKline

GSK announced that the European Commission has granted marketing authorisation for Tafinlar™ (dabrafenib)…

GlaxoSmithKline logo
GlaxoSmithKline logo

Two new GSK oral oncology treatments approved by FDA

Industry news, News / 29 May 2013 / GlaxoSmithKline

BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets approved by FDA…

GlaxoSmithKline logo

FDA approves new indication for PROMACTA® (eltrombopag)

Industry news, News / 19 November 2012 / GlaxoSmithKline

GlaxoSmithKline plc announced that the U.S. FDA has approved PROMACTA for the treatment of thrombocytopenia…

GlaxoSmithKline logo

Head-to-head study of GSK’s Votrient® vs sunitinib in advanced renal cell carcinoma meets primary endpoint

Industry news, News / 1 October 2012 / GlaxoSmithKline

The pivotal Phase III study COMPARZ has met its primary endpoint…

GlaxoSmithKline logo

European Commission grants marketing authorisation for pazopanib (Votrient®)

Industry news, News / 7 August 2012 / GlaxoSmithKline

The European Commission has granted pazopanib marketing authorisation…

GlaxoSmithKline logo

FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma

Industry news, News / 26 April 2012 / GlaxoSmithKline

GlaxoSmithKline plc announced that the U.S. FDA has approved Votrient® (pazopanib)…

GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma

Industry news, News / 24 January 2011 / GlaxoSmithKline

GlaxoSmithKline announced the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...